FDA initiative puts AR/VR at heart of home health drive
pharmaphorum
APRIL 24, 2024
A new FDA initiative is seeing how augmented reality and virtual reality (AR/VR) can make patients’ own homes an integral part of the healthcare system
Sat.Apr 20, 2024 - Fri.Apr 26, 2024
122 
Novartis nominates former Bristol Myers CEO Giovanni Caforio as its new chair. Will M&A deals follow?
Fierce Pharma
APRIL 23, 2024
Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. | Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pfizer and BioNTech commence legal action against Moderna in UK court
Pharmaceutical Technology
APRIL 24, 2024
Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in the Covid-19 vaccines development as the latest phase of a global legal fight that started yesterday (23 April), reported Reuters.
Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines
MedCity News
APRIL 25, 2024
Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics. The post Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines appeared first on MedCity News.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt
pharmaphorum
APRIL 23, 2024
After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making it the biotech's first commercial-stage product
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
Fierce Pharma
APRIL 26, 2024
Ten years after dipping its toes into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained FDA approval for the acquired treatment. | Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. The U.S. regulator has endorsed Beqvez for adults with the bleeding disorder hemophilia B.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
How Will Walgreens’ Expansion into Specialty Pharmacy Affect the Industry?
MedCity News
APRIL 25, 2024
Walgreens announced that it is expanding its specialty pharmacy offerings. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs. They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry.
Owlstone secures $6.5M for breath-based diagnostics for infectious disease
pharmaphorum
APRIL 26, 2024
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of breath-based diagnostic solutions to improve outcomes in the developing world.
Gilead writes $2.4B off Trodelvy as CEO underscores ‘time of focused execution’
Fierce Pharma
APRIL 26, 2024
After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the cornerstone of the company’s solid tumor ambition. | After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on the antibody-drug conjugate Trodelvy. With a busy year ahead across therapeutic areas, CEO Dan O'Day emphasized a "time of focused execution.
Supporting female leaders to advance cell and gene therapies
European Pharmaceutical Review
APRIL 25, 2024
Four key barriers to female career progression were explored during a panel at the UK 2024 Advanced Therapies conference in March. Hosted by members of the professional women’s networking group CGT Circle, the session explored factors that could be contributing to the current imbalance for women in leadership positions within the cell and gene therapy (CGT) sector.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery
MedCity News
APRIL 23, 2024
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types of immune cells. The post FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery appeared first on MedCity News.
ReferralMD Expands Digital Front Door with Conversational AI Patient Registration & Intake
Referral MD
APRIL 23, 2024
ReferralMD, a leader in healthcare technology solutions, is excited to announce the expansion of its Digital Front Door offering using the latest innovation in conversational AI. The Patient Registration & Intake Solution, powered by conversational AI, reimagines how patients engage with healthcare providers. With the healthcare technology market becoming more competitive than ever, ReferralMD differentiates itself with its comprehensive platform, including Digital Front Door, eConsults, R
Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche: Evaluate
Fierce Pharma
APRIL 23, 2024
The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But thanks to blockbuster meds across wider disease areas and other challenges, the lucrative market may soon slow down for the first time in years.
Clarivate welcomes the Barcelona Declaration on Open Research Information
Clarivate
APRIL 24, 2024
As long-time advocates for the principles of open research, we welcome the Barcelona Declaration on Open Research Information. We know that navigating the transition to open research is important to the scientific and scholarly community, and as a valued publisher-neutral partner, we help make that transition as seamless as possible with the tools and intelligence they need.
Providence Ordered to Pay $200M for ‘Systemic Wage Violations’
MedCity News
APRIL 24, 2024
More than 33,000 Providence employees filed a class-action complaint against the health system in 2021, alleging that it had been withholding their wages by denying them breaks and rounding down their working hours. Last week, Providence was ordered to pay more than $200 million in damages — a decision that “sends a message to healthcare corporations,” according to an attorney representing the workers.
Health Canada approves Merck’s KEYTRUDA for gastric cancer treatment
Pharmaceutical Technology
APRIL 22, 2024
Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.
Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD
Fierce Pharma
APRIL 24, 2024
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea had on the upward trajectory of Roche’s Vabysmo? Not much, according to sales figures released by Roche.
LogiPharma Europe 2024: LogiPharma Commercial Director Discusses Themes of the Show
Pharmaceutical Commerce
APRIL 23, 2024
In an interview with Pharma Commerce Associate Editor Nicholas Saraceno, Will Robinson, Commercial Director, LogiPharma, talks themes of this year's event and future plans for the show.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Johns Hopkins Is Teaming Up With Healthy.io to Improve Diabetic Patients’ Wound Care
MedCity News
APRIL 26, 2024
Johns Hopkins Hospital teamed up with Healthy.io, a company that offers smartphone-based technology to improve wound care management for diabetic patients. The partners are conducting a 120-person study to measure the impact of the startup’s technology. The post Johns Hopkins Is Teaming Up With Healthy.io to Improve Diabetic Patients’ Wound Care appeared first on MedCity News.
EC approves Pfizer’s Emblaveo for multidrug-resistant infections
Pharmaceutical Technology
APRIL 23, 2024
The European Commission (EC) has granted marketing authorisation for Pfizer’s EMBLAVEO (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options are limited.
Eli Lilly inks deal to acquire Nexus manufacturing plant in WI as Mounjaro and Zepbound shortages drag on
Fierce Pharma
APRIL 23, 2024
As doctors and patients in the U.S. | As doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is forging ahead on its quest to expand capacity for its injectable medicines.
AbbVie JAK inhibitor shows potential in novel atopic dermatitis head-to-head trial
European Pharmaceutical Review
APRIL 26, 2024
AbbVie has revealed positive topline results from the first head-to-head trial in atopic dermatitis assessing RINVOQ ® (upadacitinib) at a starting dose of 15mg daily versus DUPIXENT ® ( dupilumab ) at its labelled dose. The Phase IIIb/IV LEVEL UP study evaluated the efficacy and safety of these drugs in individuals 12 years old and older with moderate-to-severe atopic dermatitis.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
It’s Time to Give Patients a Seat at the Table
MedCity News
APRIL 24, 2024
Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design. The post It’s Time to Give Patients a Seat at the Table appeared first on MedCity News.
Avidity Biosciences gets grant for polynucleic acid conjugate for treating FSHD through rna interference
Pharmaceutical Technology
APRIL 22, 2024
Discover how Avidity Biosciences' patented polynucleic acid molecule conjugate targets the DUX4 gene to combat FSHD. Learn more about this groundbreaking approach in gene therapy.
AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod
Fierce Pharma
APRIL 26, 2024
AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. | As Humira continues its sales free fall, newer Skyrizi is proving a worthy successor with nearly matching sales ahead of an upcoming FDA decision in ulcerative colitis.
Widening adoption of animal-free reagents for endotoxin testing
European Pharmaceutical Review
APRIL 22, 2024
The USP Microbiology Expert Committee is due to vote on the proposed Chapter <86> to approve bacterial endotoxin testing using non-animal derived reagents between 21 June and 1 July 2024. Jaap Venema , Chief Science Officer, USP shared with EPR that the chapter is helping to guide manufacturers how to the adopt these methods and provides “a path to wider adoption”.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
BMI: A Flawed Measure of Health
MedCity News
APRIL 26, 2024
It’s time we move beyond BMI and adopt a holistic approach to truly gauge health. The post BMI: A Flawed Measure of Health appeared first on MedCity News.
With $75m cash injection, SynOx plans ph3 rare tumour trial
pharmaphorum
APRIL 22, 2024
Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials. TGCT is a rare disease affecting the joints and tendons caused by overproduction of the protein CSF-1, which stimulates the proliferation of various cell types, inflammation, and destruction of the matrix of the joint.
AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy
Fierce Pharma
APRIL 25, 2024
After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin. | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.
Generics propelling pharmaceutical parenteral packaging market
European Pharmaceutical Review
APRIL 25, 2024
Research on the global pharmaceutical parenteral packaging market by InsightAce Analytic Pvt. Ltd. has predicted that the sector will value $18.85 billion by 2031. This is aligned with a CAGR of 4.47 percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally.
Let's personalize your content